- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05016466
GOLD 0 - DLCO 1: A Look Beyond the Obstruction. Is Spirometry Enough for COPD (Chronic Obstructive Pulmonary Disease) Screening?
GOLD 0 - DLCO 1: A Look Beyond the Obstruction. Is Spirometry Enough for COPD Screening?
This is a multicenter observational prospective study in smokers or ex-smokers with cumulative exposure ≥ 10 a / p (years / pack) with respiratory symptoms and presenting a normal spirometry.
The patients who sign the corresponding informed consent, will undergo a DLCO and will be divided into two groups according to the result:
- Group I. Patients with DLCO <80%.
- Group II Patients with DLCO≥80%.
Both groups will be followed for 5 years.
Studieoversikt
Status
Intervensjon / Behandling
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Cruz González, PhD
- Telefonnummer: 0034961973677
- E-post: cruz.gonzalez@uv.es
Studiesteder
-
-
Valencian Community
-
Valencia, Valencian Community, Spania, 46010
- Hospital Clínico Universitario de Valencia
-
Ta kontakt med:
- cruz Gonzalez, PhD
- Telefonnummer: 0034961973977
- E-post: cruz.gonzalez@uv.es
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Age ≥18 years. The participant or his / her legal representative is willing and able to give informed consent to participate in the study.
- Female or male patients with age equal to or greater than 18 years.
- Smokers or ex-smokers with cumulative exposure ≥ 10 a / p
- Respiratory symptoms
- Normal spirometry.
Exclusion Criteria:
- Age under 18 years.
- Participation in another clinical study.
- Patients with a life expectancy of less than 2 years due to neoplasms or other serious systemic diseases.
- Refusal to sing informed consent.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
---|---|
Group I. Patients with DLCO <80%.
Patients with DLCO <80% will be followed at baseline and once a year during the study
|
Patients will followed during 5 years, Annual follo-up visits will be carried out during this period
|
Group II. Patients with DLCO ≥ 80%.
Patients with DLCO ≥80% only will be followed at baseline and year 5.
|
Patients will followed during 5 years, and only 2 visits , baseline and 5 years
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Changes from baseline of Diffusion Capacity (DLCO) at 5 years
Tidsramme: through study completion, an average of 5 years
|
To determine the value of DLCO in COPD screening in smokers and ex-smokers with respiratory symptoms and normal spirometry (GOLD 0)
|
through study completion, an average of 5 years
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Risk factors associated to the development of COPD
Tidsramme: through study completion, an average of 5 years
|
Risk factors associated to the development of COPD
|
through study completion, an average of 5 years
|
Changes from baseline of inflammatory Markers at 2 and 5 years
Tidsramme: 2 and 5 years
|
To Study soluble receptors involved in inflammation processes and tissue repair in early disease stages.
|
2 and 5 years
|
Oxidative stress
Tidsramme: through study completion, an average of 5 years
|
To Study of oxidative stress parameters in early disease stages
|
through study completion, an average of 5 years
|
Diffusion study
Tidsramme: through study completion, an average of 5 years
|
To Characterize patients in stage 0 of GOLD with impaired diffusion
|
through study completion, an average of 5 years
|
Changes from baseline of High Resolution Computed Tomography (HRTC) at 5 years
Tidsramme: Baseline and 5 years
|
To determine changes in HRCT to identify subgroups of patients with different clinical and evolutionary trajectories
|
Baseline and 5 years
|
Airflow limitation Study
Tidsramme: through study completion, an average of 5 years
|
To Investigate the contribution of measuring lung volumes for the diagnosis of COPD when there is no evidence of airflow limitation in spirometry (GOLD 0).
|
through study completion, an average of 5 years
|
Gender differences in value of diffusion (DLCO)
Tidsramme: through study completion, an average of 5 years
|
To assess if there are differences between men and women with diffusion disorder
|
through study completion, an average of 5 years
|
Childhood background
Tidsramme: Baseline
|
To assess whether factors, such as the effect of lung development during childhood and adolescence, bronchial hyperreactivity and / or the role of infections influences the risk of developing the disease or its progression.
|
Baseline
|
Comorbidity
Tidsramme: through study completion, an average of 5 years
|
To characterize the comorbidities associated with GOLD 0 patients and altered diffusion.
|
through study completion, an average of 5 years
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studieleder: Cruz González, PhD, Hospital Clínico Universitario de Valencia
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- GOLD 0-DLCO 1
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .